# Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell Antibody

> **NCT06358638** · PHASE2 · RECRUITING · sponsor: **Children's National Research Institute** · enrollment: 12 (estimated)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **DRUG:** Daratumumab
- **DRUG:** Alemtuzumab
- **DRUG:** Sirolimus
- **RADIATION:** Total Body Irradiation

## Key facts

- **NCT ID:** NCT06358638
- **Lead sponsor:** Children's National Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-03
- **Primary completion:** 2044-09
- **Final completion:** 2054-09
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2025-09-26

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06358638

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06358638, "Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell Antibody". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06358638. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*